nodes	percent_of_prediction	percent_of_DWPC	metapath
Pazopanib—kidney cancer—liver cancer	0.341	1	CtDrD
Pazopanib—KDR—liver cancer	0.147	1	CbGaD
Pazopanib—AURKC—Sorafenib—liver cancer	0.0387	0.106	CbGbCtD
Pazopanib—FLT1—Sorafenib—liver cancer	0.0387	0.106	CbGbCtD
Pazopanib—FGFR1—Sorafenib—liver cancer	0.0324	0.0889	CbGbCtD
Pazopanib—FLT4—Sorafenib—liver cancer	0.0324	0.0889	CbGbCtD
Pazopanib—KDR—Sorafenib—liver cancer	0.028	0.0768	CbGbCtD
Pazopanib—EPHB6—Sorafenib—liver cancer	0.0248	0.0679	CbGbCtD
Pazopanib—PDGFRA—Sorafenib—liver cancer	0.0222	0.061	CbGbCtD
Pazopanib—CSF1R—Sorafenib—liver cancer	0.0222	0.061	CbGbCtD
Pazopanib—KIT—Sorafenib—liver cancer	0.0222	0.061	CbGbCtD
Pazopanib—STK10—Sorafenib—liver cancer	0.0222	0.061	CbGbCtD
Pazopanib—PDGFRB—Sorafenib—liver cancer	0.0202	0.0555	CbGbCtD
Pazopanib—MAP2K5—Sorafenib—liver cancer	0.0202	0.0555	CbGbCtD
Pazopanib—MAP3K19—Sorafenib—liver cancer	0.0186	0.051	CbGbCtD
Pazopanib—UGT1A1—Sorafenib—liver cancer	0.00668	0.0183	CbGbCtD
Pazopanib—ABCG2—Sorafenib—liver cancer	0.00367	0.0101	CbGbCtD
Pazopanib—ABCG2—Doxorubicin—liver cancer	0.00223	0.00611	CbGbCtD
Pazopanib—CYP2C8—Sorafenib—liver cancer	0.00196	0.00537	CbGbCtD
Pazopanib—FLT1—umbilical vein—liver cancer	0.00183	0.0989	CbGeAlD
Pazopanib—KDR—umbilical vein—liver cancer	0.00154	0.0836	CbGeAlD
Pazopanib—CYP1A2—Sorafenib—liver cancer	0.00151	0.00416	CbGbCtD
Pazopanib—ABCB1—Sorafenib—liver cancer	0.00132	0.00363	CbGbCtD
Pazopanib—CYP2D6—Sorafenib—liver cancer	0.00125	0.00342	CbGbCtD
Pazopanib—ABCB1—Doxorubicin—liver cancer	0.000804	0.0022	CbGbCtD
Pazopanib—CYP3A4—Sorafenib—liver cancer	0.000794	0.00218	CbGbCtD
Pazopanib—FGFR3—embryo—liver cancer	0.000785	0.0425	CbGeAlD
Pazopanib—CYP2D6—Doxorubicin—liver cancer	0.000757	0.00208	CbGbCtD
Pazopanib—PDGFRA—gall bladder—liver cancer	0.000704	0.0381	CbGeAlD
Pazopanib—MAP3K9—liver—liver cancer	0.000614	0.0332	CbGeAlD
Pazopanib—FLT4—embryo—liver cancer	0.000613	0.0332	CbGeAlD
Pazopanib—KIT—gall bladder—liver cancer	0.000563	0.0305	CbGeAlD
Pazopanib—PDGFRB—gall bladder—liver cancer	0.00055	0.0298	CbGeAlD
Pazopanib—FGF1—embryo—liver cancer	0.000544	0.0295	CbGeAlD
Pazopanib—FGFR2—embryo—liver cancer	0.000514	0.0278	CbGeAlD
Pazopanib—CYP3A4—Doxorubicin—liver cancer	0.000482	0.00132	CbGbCtD
Pazopanib—FLT1—embryo—liver cancer	0.000476	0.0258	CbGeAlD
Pazopanib—TAOK1—liver—liver cancer	0.000461	0.0249	CbGeAlD
Pazopanib—PDGFRA—embryo—liver cancer	0.000446	0.0242	CbGeAlD
Pazopanib—SH2B3—liver—liver cancer	0.000434	0.0235	CbGeAlD
Pazopanib—KDR—embryo—liver cancer	0.000403	0.0218	CbGeAlD
Pazopanib—CSF1R—embryo—liver cancer	0.000393	0.0213	CbGeAlD
Pazopanib—STK16—liver—liver cancer	0.000369	0.02	CbGeAlD
Pazopanib—LYN—liver—liver cancer	0.000365	0.0198	CbGeAlD
Pazopanib—FGFR3—liver—liver cancer	0.000363	0.0197	CbGeAlD
Pazopanib—RIOK2—liver—liver cancer	0.000363	0.0197	CbGeAlD
Pazopanib—KIT—embryo—liver cancer	0.000357	0.0193	CbGeAlD
Pazopanib—PDGFRB—embryo—liver cancer	0.000349	0.0189	CbGeAlD
Pazopanib—STK36—liver—liver cancer	0.000326	0.0177	CbGeAlD
Pazopanib—PI4KB—liver—liver cancer	0.000321	0.0174	CbGeAlD
Pazopanib—LIMK2—liver—liver cancer	0.000315	0.0171	CbGeAlD
Pazopanib—PLK4—Idarubicin—Epirubicin—liver cancer	0.000299	0.26	CbGdCrCtD
Pazopanib—PLK4—Doxorubicin—Epirubicin—liver cancer	0.000299	0.26	CbGdCrCtD
Pazopanib—FLT4—liver—liver cancer	0.000283	0.0153	CbGeAlD
Pazopanib—PIP4K2C—liver—liver cancer	0.000282	0.0153	CbGeAlD
Pazopanib—FGFR1—liver—liver cancer	0.00028	0.0151	CbGeAlD
Pazopanib—PLK4—Epirubicin—Doxorubicin—liver cancer	0.000277	0.24	CbGdCrCtD
Pazopanib—PLK4—Idarubicin—Doxorubicin—liver cancer	0.000277	0.24	CbGdCrCtD
Pazopanib—MAP3K2—liver—liver cancer	0.000267	0.0145	CbGeAlD
Pazopanib—FGF1—liver—liver cancer	0.000252	0.0136	CbGeAlD
Pazopanib—LCK—liver—liver cancer	0.00025	0.0135	CbGeAlD
Pazopanib—FGFR2—liver—liver cancer	0.000238	0.0129	CbGeAlD
Pazopanib—FLT1—liver—liver cancer	0.00022	0.0119	CbGeAlD
Pazopanib—STK10—liver—liver cancer	0.000209	0.0113	CbGeAlD
Pazopanib—TAOK3—liver—liver cancer	0.000208	0.0112	CbGeAlD
Pazopanib—PDGFRA—liver—liver cancer	0.000206	0.0112	CbGeAlD
Pazopanib—UGT1A1—liver—liver cancer	0.000197	0.0107	CbGeAlD
Pazopanib—KDR—liver—liver cancer	0.000186	0.0101	CbGeAlD
Pazopanib—MAP2K5—liver—liver cancer	0.000186	0.0101	CbGeAlD
Pazopanib—CSF1R—liver—liver cancer	0.000182	0.00984	CbGeAlD
Pazopanib—KIT—liver—liver cancer	0.000165	0.00894	CbGeAlD
Pazopanib—SLCO1B1—liver—liver cancer	0.000164	0.00887	CbGeAlD
Pazopanib—PDGFRB—liver—liver cancer	0.000161	0.00873	CbGeAlD
Pazopanib—Skin discolouration—Epirubicin—liver cancer	0.00012	0.00219	CcSEcCtD
Pazopanib—Hyperbilirubinaemia—Epirubicin—liver cancer	0.000119	0.00217	CcSEcCtD
Pazopanib—Anaemia—Sorafenib—liver cancer	0.000119	0.00216	CcSEcCtD
Pazopanib—Neoplasm malignant—Doxorubicin—liver cancer	0.000118	0.00214	CcSEcCtD
Pazopanib—Syncope—Sorafenib—liver cancer	0.000115	0.00209	CcSEcCtD
Pazopanib—Leukopenia—Sorafenib—liver cancer	0.000115	0.00209	CcSEcCtD
Pazopanib—Blood bilirubin increased—Epirubicin—liver cancer	0.000115	0.00209	CcSEcCtD
Pazopanib—Creatinine increased—Epirubicin—liver cancer	0.000114	0.00207	CcSEcCtD
Pazopanib—Loss of consciousness—Sorafenib—liver cancer	0.000113	0.00205	CcSEcCtD
Pazopanib—Cough—Sorafenib—liver cancer	0.000112	0.00204	CcSEcCtD
Pazopanib—Skin discolouration—Doxorubicin—liver cancer	0.000111	0.00202	CcSEcCtD
Pazopanib—Rectal haemorrhage—Doxorubicin—liver cancer	0.000111	0.00202	CcSEcCtD
Pazopanib—Hypertension—Sorafenib—liver cancer	0.000111	0.00202	CcSEcCtD
Pazopanib—Hyperbilirubinaemia—Doxorubicin—liver cancer	0.00011	0.00201	CcSEcCtD
Pazopanib—Musculoskeletal pain—Epirubicin—liver cancer	0.00011	0.002	CcSEcCtD
Pazopanib—Arthralgia—Sorafenib—liver cancer	0.000109	0.00199	CcSEcCtD
Pazopanib—Myalgia—Sorafenib—liver cancer	0.000109	0.00199	CcSEcCtD
Pazopanib—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—liver cancer	0.000109	0.00197	CcSEcCtD
Pazopanib—Hiccups—Epirubicin—liver cancer	0.000109	0.00197	CcSEcCtD
Pazopanib—Pulmonary embolism—Epirubicin—liver cancer	0.000109	0.00197	CcSEcCtD
Pazopanib—Phosphatase alkaline increased—Epirubicin—liver cancer	0.000109	0.00197	CcSEcCtD
Pazopanib—Dry mouth—Sorafenib—liver cancer	0.000107	0.00194	CcSEcCtD
Pazopanib—Blood bilirubin increased—Doxorubicin—liver cancer	0.000106	0.00193	CcSEcCtD
Pazopanib—Melaena—Epirubicin—liver cancer	0.000106	0.00193	CcSEcCtD
Pazopanib—Creatinine increased—Doxorubicin—liver cancer	0.000105	0.00192	CcSEcCtD
Pazopanib—Infection—Sorafenib—liver cancer	0.000104	0.00189	CcSEcCtD
Pazopanib—Skin exfoliation—Epirubicin—liver cancer	0.000104	0.00189	CcSEcCtD
Pazopanib—Shock—Sorafenib—liver cancer	0.000103	0.00188	CcSEcCtD
Pazopanib—Nervous system disorder—Sorafenib—liver cancer	0.000103	0.00187	CcSEcCtD
Pazopanib—Thrombocytopenia—Sorafenib—liver cancer	0.000103	0.00187	CcSEcCtD
Pazopanib—Blood urea increased—Epirubicin—liver cancer	0.000102	0.00186	CcSEcCtD
Pazopanib—Skin disorder—Sorafenib—liver cancer	0.000102	0.00185	CcSEcCtD
Pazopanib—Musculoskeletal pain—Doxorubicin—liver cancer	0.000102	0.00185	CcSEcCtD
Pazopanib—Phosphatase alkaline increased—Doxorubicin—liver cancer	0.0001	0.00183	CcSEcCtD
Pazopanib—Pulmonary embolism—Doxorubicin—liver cancer	0.0001	0.00183	CcSEcCtD
Pazopanib—Hiccups—Doxorubicin—liver cancer	0.0001	0.00183	CcSEcCtD
Pazopanib—Anorexia—Sorafenib—liver cancer	9.99e-05	0.00182	CcSEcCtD
Pazopanib—Mouth ulceration—Epirubicin—liver cancer	9.81e-05	0.00179	CcSEcCtD
Pazopanib—Melaena—Doxorubicin—liver cancer	9.81e-05	0.00178	CcSEcCtD
Pazopanib—ABCB1—embryo—liver cancer	9.66e-05	0.00523	CbGeAlD
Pazopanib—Skin exfoliation—Doxorubicin—liver cancer	9.59e-05	0.00174	CcSEcCtD
Pazopanib—Musculoskeletal discomfort—Sorafenib—liver cancer	9.54e-05	0.00174	CcSEcCtD
Pazopanib—Blood urea increased—Doxorubicin—liver cancer	9.48e-05	0.00172	CcSEcCtD
Pazopanib—Dyspnoea—Sorafenib—liver cancer	9.34e-05	0.0017	CcSEcCtD
Pazopanib—CYP2C8—liver—liver cancer	9.32e-05	0.00504	CbGeAlD
Pazopanib—Dyspepsia—Sorafenib—liver cancer	9.22e-05	0.00168	CcSEcCtD
Pazopanib—Decreased appetite—Sorafenib—liver cancer	9.11e-05	0.00166	CcSEcCtD
Pazopanib—Mouth ulceration—Doxorubicin—liver cancer	9.08e-05	0.00165	CcSEcCtD
Pazopanib—ABCG2—liver—liver cancer	9.06e-05	0.00491	CbGeAlD
Pazopanib—Blood alkaline phosphatase increased—Epirubicin—liver cancer	9.06e-05	0.00165	CcSEcCtD
Pazopanib—Gastrointestinal disorder—Sorafenib—liver cancer	9.04e-05	0.00165	CcSEcCtD
Pazopanib—Fatigue—Sorafenib—liver cancer	9.03e-05	0.00164	CcSEcCtD
Pazopanib—Hepatic function abnormal—Epirubicin—liver cancer	9.01e-05	0.00164	CcSEcCtD
Pazopanib—Pain—Sorafenib—liver cancer	8.96e-05	0.00163	CcSEcCtD
Pazopanib—Hepatic failure—Epirubicin—liver cancer	8.77e-05	0.0016	CcSEcCtD
Pazopanib—CYP1A2—liver—liver cancer	8.72e-05	0.00472	CbGeAlD
Pazopanib—Cardiac failure congestive—Epirubicin—liver cancer	8.69e-05	0.00158	CcSEcCtD
Pazopanib—Gastrointestinal pain—Sorafenib—liver cancer	8.57e-05	0.00156	CcSEcCtD
Pazopanib—Hot flush—Epirubicin—liver cancer	8.42e-05	0.00153	CcSEcCtD
Pazopanib—Blood alkaline phosphatase increased—Doxorubicin—liver cancer	8.38e-05	0.00152	CcSEcCtD
Pazopanib—Menopausal symptoms—Epirubicin—liver cancer	8.35e-05	0.00152	CcSEcCtD
Pazopanib—Hepatic function abnormal—Doxorubicin—liver cancer	8.34e-05	0.00152	CcSEcCtD
Pazopanib—Abdominal pain—Sorafenib—liver cancer	8.28e-05	0.00151	CcSEcCtD
Pazopanib—Hepatic failure—Doxorubicin—liver cancer	8.11e-05	0.00148	CcSEcCtD
Pazopanib—Cardiac failure—Epirubicin—liver cancer	8.07e-05	0.00147	CcSEcCtD
Pazopanib—Cerebrovascular accident—Epirubicin—liver cancer	8.04e-05	0.00146	CcSEcCtD
Pazopanib—Lethargy—Epirubicin—liver cancer	8.04e-05	0.00146	CcSEcCtD
Pazopanib—Cardiac failure congestive—Doxorubicin—liver cancer	8.04e-05	0.00146	CcSEcCtD
Pazopanib—Hyponatraemia—Epirubicin—liver cancer	7.91e-05	0.00144	CcSEcCtD
Pazopanib—Gastrointestinal haemorrhage—Epirubicin—liver cancer	7.88e-05	0.00143	CcSEcCtD
Pazopanib—Hot flush—Doxorubicin—liver cancer	7.79e-05	0.00142	CcSEcCtD
Pazopanib—Menopausal symptoms—Doxorubicin—liver cancer	7.72e-05	0.00141	CcSEcCtD
Pazopanib—Face oedema—Epirubicin—liver cancer	7.6e-05	0.00138	CcSEcCtD
Pazopanib—Asthenia—Sorafenib—liver cancer	7.52e-05	0.00137	CcSEcCtD
Pazopanib—Cardiac failure—Doxorubicin—liver cancer	7.47e-05	0.00136	CcSEcCtD
Pazopanib—Cerebrovascular accident—Doxorubicin—liver cancer	7.44e-05	0.00135	CcSEcCtD
Pazopanib—Lethargy—Doxorubicin—liver cancer	7.44e-05	0.00135	CcSEcCtD
Pazopanib—Pruritus—Sorafenib—liver cancer	7.41e-05	0.00135	CcSEcCtD
Pazopanib—Blood creatinine increased—Epirubicin—liver cancer	7.38e-05	0.00134	CcSEcCtD
Pazopanib—Dehydration—Epirubicin—liver cancer	7.33e-05	0.00133	CcSEcCtD
Pazopanib—Hyponatraemia—Doxorubicin—liver cancer	7.32e-05	0.00133	CcSEcCtD
Pazopanib—Gastrointestinal haemorrhage—Doxorubicin—liver cancer	7.29e-05	0.00133	CcSEcCtD
Pazopanib—Liver function test abnormal—Epirubicin—liver cancer	7.27e-05	0.00132	CcSEcCtD
Pazopanib—Dry skin—Epirubicin—liver cancer	7.22e-05	0.00131	CcSEcCtD
Pazopanib—Abdominal pain upper—Epirubicin—liver cancer	7.19e-05	0.00131	CcSEcCtD
Pazopanib—Diarrhoea—Sorafenib—liver cancer	7.17e-05	0.0013	CcSEcCtD
Pazopanib—Breast disorder—Epirubicin—liver cancer	7.12e-05	0.0013	CcSEcCtD
Pazopanib—Aspartate aminotransferase increased—Epirubicin—liver cancer	7.09e-05	0.00129	CcSEcCtD
Pazopanib—Nasopharyngitis—Epirubicin—liver cancer	7.04e-05	0.00128	CcSEcCtD
Pazopanib—Face oedema—Doxorubicin—liver cancer	7.04e-05	0.00128	CcSEcCtD
Pazopanib—Alanine aminotransferase increased—Epirubicin—liver cancer	6.95e-05	0.00126	CcSEcCtD
Pazopanib—Dizziness—Sorafenib—liver cancer	6.93e-05	0.00126	CcSEcCtD
Pazopanib—Abdominal distension—Epirubicin—liver cancer	6.85e-05	0.00125	CcSEcCtD
Pazopanib—Blood creatinine increased—Doxorubicin—liver cancer	6.83e-05	0.00124	CcSEcCtD
Pazopanib—Dehydration—Doxorubicin—liver cancer	6.78e-05	0.00123	CcSEcCtD
Pazopanib—Liver function test abnormal—Doxorubicin—liver cancer	6.73e-05	0.00122	CcSEcCtD
Pazopanib—Dry skin—Doxorubicin—liver cancer	6.68e-05	0.00122	CcSEcCtD
Pazopanib—Pancreatitis—Epirubicin—liver cancer	6.67e-05	0.00121	CcSEcCtD
Pazopanib—Vomiting—Sorafenib—liver cancer	6.66e-05	0.00121	CcSEcCtD
Pazopanib—Abdominal pain upper—Doxorubicin—liver cancer	6.66e-05	0.00121	CcSEcCtD
Pazopanib—Rash—Sorafenib—liver cancer	6.61e-05	0.0012	CcSEcCtD
Pazopanib—Dermatitis—Sorafenib—liver cancer	6.6e-05	0.0012	CcSEcCtD
Pazopanib—Breast disorder—Doxorubicin—liver cancer	6.59e-05	0.0012	CcSEcCtD
Pazopanib—Aspartate aminotransferase increased—Doxorubicin—liver cancer	6.56e-05	0.00119	CcSEcCtD
Pazopanib—Headache—Sorafenib—liver cancer	6.56e-05	0.00119	CcSEcCtD
Pazopanib—Nasopharyngitis—Doxorubicin—liver cancer	6.52e-05	0.00119	CcSEcCtD
Pazopanib—Alanine aminotransferase increased—Doxorubicin—liver cancer	6.43e-05	0.00117	CcSEcCtD
Pazopanib—Neutropenia—Epirubicin—liver cancer	6.37e-05	0.00116	CcSEcCtD
Pazopanib—Abdominal distension—Doxorubicin—liver cancer	6.34e-05	0.00115	CcSEcCtD
Pazopanib—CYP3A4—liver—liver cancer	6.31e-05	0.00342	CbGeAlD
Pazopanib—Nausea—Sorafenib—liver cancer	6.22e-05	0.00113	CcSEcCtD
Pazopanib—Photosensitivity reaction—Epirubicin—liver cancer	6.21e-05	0.00113	CcSEcCtD
Pazopanib—CYP2D6—liver—liver cancer	6.21e-05	0.00336	CbGeAlD
Pazopanib—Pancreatitis—Doxorubicin—liver cancer	6.18e-05	0.00112	CcSEcCtD
Pazopanib—Weight decreased—Epirubicin—liver cancer	6.16e-05	0.00112	CcSEcCtD
Pazopanib—Infestation NOS—Epirubicin—liver cancer	6.07e-05	0.0011	CcSEcCtD
Pazopanib—Infestation—Epirubicin—liver cancer	6.07e-05	0.0011	CcSEcCtD
Pazopanib—Jaundice—Epirubicin—liver cancer	5.92e-05	0.00108	CcSEcCtD
Pazopanib—Stomatitis—Epirubicin—liver cancer	5.92e-05	0.00108	CcSEcCtD
Pazopanib—Neutropenia—Doxorubicin—liver cancer	5.89e-05	0.00107	CcSEcCtD
Pazopanib—Haematuria—Epirubicin—liver cancer	5.79e-05	0.00105	CcSEcCtD
Pazopanib—Photosensitivity reaction—Doxorubicin—liver cancer	5.75e-05	0.00105	CcSEcCtD
Pazopanib—Hepatobiliary disease—Epirubicin—liver cancer	5.74e-05	0.00104	CcSEcCtD
Pazopanib—Epistaxis—Epirubicin—liver cancer	5.73e-05	0.00104	CcSEcCtD
Pazopanib—Weight decreased—Doxorubicin—liver cancer	5.7e-05	0.00104	CcSEcCtD
Pazopanib—Infestation NOS—Doxorubicin—liver cancer	5.62e-05	0.00102	CcSEcCtD
Pazopanib—Infestation—Doxorubicin—liver cancer	5.62e-05	0.00102	CcSEcCtD
Pazopanib—Bradycardia—Epirubicin—liver cancer	5.55e-05	0.00101	CcSEcCtD
Pazopanib—Haemoglobin—Epirubicin—liver cancer	5.48e-05	0.000997	CcSEcCtD
Pazopanib—Stomatitis—Doxorubicin—liver cancer	5.47e-05	0.000996	CcSEcCtD
Pazopanib—Jaundice—Doxorubicin—liver cancer	5.47e-05	0.000996	CcSEcCtD
Pazopanib—Haemorrhage—Epirubicin—liver cancer	5.45e-05	0.000992	CcSEcCtD
Pazopanib—Hypoaesthesia—Epirubicin—liver cancer	5.42e-05	0.000987	CcSEcCtD
Pazopanib—Urinary tract disorder—Epirubicin—liver cancer	5.38e-05	0.000979	CcSEcCtD
Pazopanib—Oedema peripheral—Epirubicin—liver cancer	5.37e-05	0.000977	CcSEcCtD
Pazopanib—Haematuria—Doxorubicin—liver cancer	5.36e-05	0.000975	CcSEcCtD
Pazopanib—Connective tissue disorder—Epirubicin—liver cancer	5.36e-05	0.000974	CcSEcCtD
Pazopanib—Urethral disorder—Epirubicin—liver cancer	5.34e-05	0.000972	CcSEcCtD
Pazopanib—Hepatobiliary disease—Doxorubicin—liver cancer	5.31e-05	0.000967	CcSEcCtD
Pazopanib—Epistaxis—Doxorubicin—liver cancer	5.3e-05	0.000964	CcSEcCtD
Pazopanib—Bradycardia—Doxorubicin—liver cancer	5.13e-05	0.000934	CcSEcCtD
Pazopanib—Eye disorder—Epirubicin—liver cancer	5.09e-05	0.000927	CcSEcCtD
Pazopanib—Haemoglobin—Doxorubicin—liver cancer	5.07e-05	0.000922	CcSEcCtD
Pazopanib—Flushing—Epirubicin—liver cancer	5.06e-05	0.00092	CcSEcCtD
Pazopanib—Cardiac disorder—Epirubicin—liver cancer	5.06e-05	0.00092	CcSEcCtD
Pazopanib—Haemorrhage—Doxorubicin—liver cancer	5.04e-05	0.000918	CcSEcCtD
Pazopanib—Hypoaesthesia—Doxorubicin—liver cancer	5.02e-05	0.000913	CcSEcCtD
Pazopanib—Urinary tract disorder—Doxorubicin—liver cancer	4.98e-05	0.000906	CcSEcCtD
Pazopanib—Oedema peripheral—Doxorubicin—liver cancer	4.97e-05	0.000904	CcSEcCtD
Pazopanib—Connective tissue disorder—Doxorubicin—liver cancer	4.95e-05	0.000902	CcSEcCtD
Pazopanib—Angiopathy—Epirubicin—liver cancer	4.94e-05	0.0009	CcSEcCtD
Pazopanib—Urethral disorder—Doxorubicin—liver cancer	4.94e-05	0.000899	CcSEcCtD
Pazopanib—Mediastinal disorder—Epirubicin—liver cancer	4.91e-05	0.000894	CcSEcCtD
Pazopanib—Chills—Epirubicin—liver cancer	4.89e-05	0.00089	CcSEcCtD
Pazopanib—Alopecia—Epirubicin—liver cancer	4.82e-05	0.000876	CcSEcCtD
Pazopanib—Mental disorder—Epirubicin—liver cancer	4.77e-05	0.000869	CcSEcCtD
Pazopanib—Malnutrition—Epirubicin—liver cancer	4.74e-05	0.000863	CcSEcCtD
Pazopanib—Erythema—Epirubicin—liver cancer	4.74e-05	0.000863	CcSEcCtD
Pazopanib—Eye disorder—Doxorubicin—liver cancer	4.71e-05	0.000857	CcSEcCtD
Pazopanib—Cardiac disorder—Doxorubicin—liver cancer	4.68e-05	0.000852	CcSEcCtD
Pazopanib—Flushing—Doxorubicin—liver cancer	4.68e-05	0.000852	CcSEcCtD
Pazopanib—Flatulence—Epirubicin—liver cancer	4.67e-05	0.000851	CcSEcCtD
Pazopanib—Dysgeusia—Epirubicin—liver cancer	4.65e-05	0.000845	CcSEcCtD
Pazopanib—Angiopathy—Doxorubicin—liver cancer	4.57e-05	0.000832	CcSEcCtD
Pazopanib—Muscle spasms—Epirubicin—liver cancer	4.56e-05	0.00083	CcSEcCtD
Pazopanib—Mediastinal disorder—Doxorubicin—liver cancer	4.54e-05	0.000827	CcSEcCtD
Pazopanib—Chills—Doxorubicin—liver cancer	4.52e-05	0.000823	CcSEcCtD
Pazopanib—Vision blurred—Epirubicin—liver cancer	4.47e-05	0.000814	CcSEcCtD
Pazopanib—ABCB1—liver—liver cancer	4.47e-05	0.00242	CbGeAlD
Pazopanib—Alopecia—Doxorubicin—liver cancer	4.46e-05	0.000811	CcSEcCtD
Pazopanib—Mental disorder—Doxorubicin—liver cancer	4.42e-05	0.000804	CcSEcCtD
Pazopanib—Malnutrition—Doxorubicin—liver cancer	4.39e-05	0.000799	CcSEcCtD
Pazopanib—Erythema—Doxorubicin—liver cancer	4.39e-05	0.000799	CcSEcCtD
Pazopanib—Anaemia—Epirubicin—liver cancer	4.38e-05	0.000798	CcSEcCtD
Pazopanib—Flatulence—Doxorubicin—liver cancer	4.33e-05	0.000787	CcSEcCtD
Pazopanib—Dysgeusia—Doxorubicin—liver cancer	4.3e-05	0.000782	CcSEcCtD
Pazopanib—Syncope—Epirubicin—liver cancer	4.25e-05	0.000774	CcSEcCtD
Pazopanib—Leukopenia—Epirubicin—liver cancer	4.25e-05	0.000773	CcSEcCtD
Pazopanib—Muscle spasms—Doxorubicin—liver cancer	4.22e-05	0.000768	CcSEcCtD
Pazopanib—Loss of consciousness—Epirubicin—liver cancer	4.17e-05	0.000759	CcSEcCtD
Pazopanib—Cough—Epirubicin—liver cancer	4.14e-05	0.000753	CcSEcCtD
Pazopanib—Vision blurred—Doxorubicin—liver cancer	4.14e-05	0.000753	CcSEcCtD
Pazopanib—Hypertension—Epirubicin—liver cancer	4.1e-05	0.000745	CcSEcCtD
Pazopanib—Anaemia—Doxorubicin—liver cancer	4.06e-05	0.000738	CcSEcCtD
Pazopanib—Chest pain—Epirubicin—liver cancer	4.04e-05	0.000735	CcSEcCtD
Pazopanib—Myalgia—Epirubicin—liver cancer	4.04e-05	0.000735	CcSEcCtD
Pazopanib—Arthralgia—Epirubicin—liver cancer	4.04e-05	0.000735	CcSEcCtD
Pazopanib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—liver cancer	4.01e-05	0.00073	CcSEcCtD
Pazopanib—Dry mouth—Epirubicin—liver cancer	3.95e-05	0.000719	CcSEcCtD
Pazopanib—Syncope—Doxorubicin—liver cancer	3.94e-05	0.000716	CcSEcCtD
Pazopanib—Leukopenia—Doxorubicin—liver cancer	3.93e-05	0.000715	CcSEcCtD
Pazopanib—Oedema—Epirubicin—liver cancer	3.87e-05	0.000705	CcSEcCtD
Pazopanib—Loss of consciousness—Doxorubicin—liver cancer	3.86e-05	0.000702	CcSEcCtD
Pazopanib—Infection—Epirubicin—liver cancer	3.85e-05	0.0007	CcSEcCtD
Pazopanib—Cough—Doxorubicin—liver cancer	3.83e-05	0.000697	CcSEcCtD
Pazopanib—Shock—Epirubicin—liver cancer	3.81e-05	0.000693	CcSEcCtD
Pazopanib—Nervous system disorder—Epirubicin—liver cancer	3.8e-05	0.000691	CcSEcCtD
Pazopanib—Thrombocytopenia—Epirubicin—liver cancer	3.79e-05	0.00069	CcSEcCtD
Pazopanib—Hypertension—Doxorubicin—liver cancer	3.79e-05	0.00069	CcSEcCtD
Pazopanib—Skin disorder—Epirubicin—liver cancer	3.76e-05	0.000684	CcSEcCtD
Pazopanib—Hyperhidrosis—Epirubicin—liver cancer	3.74e-05	0.000681	CcSEcCtD
Pazopanib—Arthralgia—Doxorubicin—liver cancer	3.74e-05	0.00068	CcSEcCtD
Pazopanib—Chest pain—Doxorubicin—liver cancer	3.74e-05	0.00068	CcSEcCtD
Pazopanib—Myalgia—Doxorubicin—liver cancer	3.74e-05	0.00068	CcSEcCtD
Pazopanib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—liver cancer	3.71e-05	0.000675	CcSEcCtD
Pazopanib—Anorexia—Epirubicin—liver cancer	3.69e-05	0.000672	CcSEcCtD
Pazopanib—Dry mouth—Doxorubicin—liver cancer	3.65e-05	0.000665	CcSEcCtD
Pazopanib—Oedema—Doxorubicin—liver cancer	3.58e-05	0.000652	CcSEcCtD
Pazopanib—Infection—Doxorubicin—liver cancer	3.56e-05	0.000648	CcSEcCtD
Pazopanib—Musculoskeletal discomfort—Epirubicin—liver cancer	3.53e-05	0.000642	CcSEcCtD
Pazopanib—Shock—Doxorubicin—liver cancer	3.52e-05	0.000641	CcSEcCtD
Pazopanib—Nervous system disorder—Doxorubicin—liver cancer	3.51e-05	0.000639	CcSEcCtD
Pazopanib—Thrombocytopenia—Doxorubicin—liver cancer	3.51e-05	0.000638	CcSEcCtD
Pazopanib—Insomnia—Epirubicin—liver cancer	3.5e-05	0.000637	CcSEcCtD
Pazopanib—Skin disorder—Doxorubicin—liver cancer	3.48e-05	0.000633	CcSEcCtD
Pazopanib—Paraesthesia—Epirubicin—liver cancer	3.48e-05	0.000633	CcSEcCtD
Pazopanib—Hyperhidrosis—Doxorubicin—liver cancer	3.46e-05	0.00063	CcSEcCtD
Pazopanib—Dyspnoea—Epirubicin—liver cancer	3.45e-05	0.000628	CcSEcCtD
Pazopanib—Somnolence—Epirubicin—liver cancer	3.44e-05	0.000626	CcSEcCtD
Pazopanib—Anorexia—Doxorubicin—liver cancer	3.41e-05	0.000621	CcSEcCtD
Pazopanib—Dyspepsia—Epirubicin—liver cancer	3.41e-05	0.00062	CcSEcCtD
Pazopanib—Decreased appetite—Epirubicin—liver cancer	3.37e-05	0.000612	CcSEcCtD
Pazopanib—Gastrointestinal disorder—Epirubicin—liver cancer	3.34e-05	0.000608	CcSEcCtD
Pazopanib—Fatigue—Epirubicin—liver cancer	3.34e-05	0.000607	CcSEcCtD
Pazopanib—Pain—Epirubicin—liver cancer	3.31e-05	0.000602	CcSEcCtD
Pazopanib—Musculoskeletal discomfort—Doxorubicin—liver cancer	3.26e-05	0.000594	CcSEcCtD
Pazopanib—Insomnia—Doxorubicin—liver cancer	3.24e-05	0.00059	CcSEcCtD
Pazopanib—Paraesthesia—Doxorubicin—liver cancer	3.22e-05	0.000585	CcSEcCtD
Pazopanib—Dyspnoea—Doxorubicin—liver cancer	3.19e-05	0.000581	CcSEcCtD
Pazopanib—Somnolence—Doxorubicin—liver cancer	3.18e-05	0.00058	CcSEcCtD
Pazopanib—Gastrointestinal pain—Epirubicin—liver cancer	3.17e-05	0.000576	CcSEcCtD
Pazopanib—Dyspepsia—Doxorubicin—liver cancer	3.15e-05	0.000574	CcSEcCtD
Pazopanib—Decreased appetite—Doxorubicin—liver cancer	3.11e-05	0.000567	CcSEcCtD
Pazopanib—Gastrointestinal disorder—Doxorubicin—liver cancer	3.09e-05	0.000563	CcSEcCtD
Pazopanib—Fatigue—Doxorubicin—liver cancer	3.09e-05	0.000562	CcSEcCtD
Pazopanib—Pain—Doxorubicin—liver cancer	3.06e-05	0.000557	CcSEcCtD
Pazopanib—Abdominal pain—Epirubicin—liver cancer	3.06e-05	0.000557	CcSEcCtD
Pazopanib—Gastrointestinal pain—Doxorubicin—liver cancer	2.93e-05	0.000533	CcSEcCtD
Pazopanib—Abdominal pain—Doxorubicin—liver cancer	2.83e-05	0.000515	CcSEcCtD
Pazopanib—Asthenia—Epirubicin—liver cancer	2.78e-05	0.000505	CcSEcCtD
Pazopanib—Pruritus—Epirubicin—liver cancer	2.74e-05	0.000498	CcSEcCtD
Pazopanib—Diarrhoea—Epirubicin—liver cancer	2.65e-05	0.000482	CcSEcCtD
Pazopanib—Asthenia—Doxorubicin—liver cancer	2.57e-05	0.000468	CcSEcCtD
Pazopanib—Dizziness—Epirubicin—liver cancer	2.56e-05	0.000466	CcSEcCtD
Pazopanib—Pruritus—Doxorubicin—liver cancer	2.53e-05	0.000461	CcSEcCtD
Pazopanib—Vomiting—Epirubicin—liver cancer	2.46e-05	0.000448	CcSEcCtD
Pazopanib—Diarrhoea—Doxorubicin—liver cancer	2.45e-05	0.000446	CcSEcCtD
Pazopanib—Rash—Epirubicin—liver cancer	2.44e-05	0.000444	CcSEcCtD
Pazopanib—Dermatitis—Epirubicin—liver cancer	2.44e-05	0.000444	CcSEcCtD
Pazopanib—Headache—Epirubicin—liver cancer	2.43e-05	0.000441	CcSEcCtD
Pazopanib—Dizziness—Doxorubicin—liver cancer	2.37e-05	0.000431	CcSEcCtD
Pazopanib—Nausea—Epirubicin—liver cancer	2.3e-05	0.000418	CcSEcCtD
Pazopanib—Vomiting—Doxorubicin—liver cancer	2.28e-05	0.000414	CcSEcCtD
Pazopanib—Rash—Doxorubicin—liver cancer	2.26e-05	0.000411	CcSEcCtD
Pazopanib—Dermatitis—Doxorubicin—liver cancer	2.26e-05	0.000411	CcSEcCtD
Pazopanib—Headache—Doxorubicin—liver cancer	2.24e-05	0.000408	CcSEcCtD
Pazopanib—Nausea—Doxorubicin—liver cancer	2.13e-05	0.000387	CcSEcCtD
Pazopanib—CYP2C8—Metabolism—CYP1A1—liver cancer	7.84e-07	1.07e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—CDKN1A—liver cancer	7.84e-07	1.07e-05	CbGpPWpGaD
Pazopanib—LCK—Immune System—STAT3—liver cancer	7.82e-07	1.07e-05	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—KRAS—liver cancer	7.81e-07	1.07e-05	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—HMOX1—liver cancer	7.73e-07	1.06e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—KRAS—liver cancer	7.73e-07	1.06e-05	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—PIK3CA—liver cancer	7.71e-07	1.06e-05	CbGpPWpGaD
Pazopanib—KIT—Disease—HRAS—liver cancer	7.7e-07	1.06e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—PIK3CA—liver cancer	7.69e-07	1.05e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—MAPK8—liver cancer	7.67e-07	1.05e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—CDKN1B—liver cancer	7.65e-07	1.05e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—MAPK8—liver cancer	7.65e-07	1.05e-05	CbGpPWpGaD
Pazopanib—FGFR3—Signaling Pathways—IL6—liver cancer	7.64e-07	1.05e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—VEGFA—liver cancer	7.6e-07	1.04e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—CYP2E1—liver cancer	7.59e-07	1.04e-05	CbGpPWpGaD
Pazopanib—ABCG2—Metabolism—PIK3CB—liver cancer	7.58e-07	1.04e-05	CbGpPWpGaD
Pazopanib—FGFR1—Immune System—IL6—liver cancer	7.58e-07	1.04e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Immune System—IL6—liver cancer	7.56e-07	1.04e-05	CbGpPWpGaD
Pazopanib—LYN—Immune System—PIK3CA—liver cancer	7.53e-07	1.03e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—STAT3—liver cancer	7.52e-07	1.03e-05	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—PIK3CA—liver cancer	7.52e-07	1.03e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—PIK3CD—liver cancer	7.51e-07	1.03e-05	CbGpPWpGaD
Pazopanib—FGFR2—Disease—IL6—liver cancer	7.51e-07	1.03e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—CASP3—liver cancer	7.5e-07	1.03e-05	CbGpPWpGaD
Pazopanib—FGFR2—Immune System—AKT1—liver cancer	7.5e-07	1.03e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—CDKN1B—liver cancer	7.49e-07	1.03e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—IL2—liver cancer	7.49e-07	1.03e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—VEGFA—liver cancer	7.46e-07	1.02e-05	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—TP53—liver cancer	7.46e-07	1.02e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—SERPINE1—liver cancer	7.43e-07	1.02e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—STAT3—liver cancer	7.39e-07	1.01e-05	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—GSTP1—liver cancer	7.39e-07	1.01e-05	CbGpPWpGaD
Pazopanib—KIT—Disease—IL6—liver cancer	7.37e-07	1.01e-05	CbGpPWpGaD
Pazopanib—KIT—Immune System—AKT1—liver cancer	7.37e-07	1.01e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	7.35e-07	1.01e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—CASP3—liver cancer	7.34e-07	1.01e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—IL2—liver cancer	7.33e-07	1e-05	CbGpPWpGaD
Pazopanib—FGFR1—Disease—HRAS—liver cancer	7.31e-07	1e-05	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—MTHFR—liver cancer	7.31e-07	1e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—CCND1—liver cancer	7.3e-07	1e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Disease—HRAS—liver cancer	7.29e-07	9.99e-06	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—HMOX1—liver cancer	7.29e-07	9.98e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—JUN—liver cancer	7.29e-07	9.98e-06	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—TP53—liver cancer	7.27e-07	9.97e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—CTNNB1—liver cancer	7.23e-07	9.91e-06	CbGpPWpGaD
Pazopanib—LCK—Disease—STAT3—liver cancer	7.22e-07	9.9e-06	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—GSTM1—liver cancer	7.2e-07	9.87e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—HPGDS—liver cancer	7.19e-07	9.85e-06	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—PIK3CA—liver cancer	7.17e-07	9.83e-06	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—PPARA—liver cancer	7.17e-07	9.83e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—CCND1—liver cancer	7.15e-07	9.8e-06	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—HRAS—liver cancer	7.14e-07	9.78e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—JUN—liver cancer	7.13e-07	9.77e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—HRAS—liver cancer	7.11e-07	9.75e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—CYCS—liver cancer	7.1e-07	9.73e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—PIK3CA—liver cancer	7.1e-07	9.73e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—MMP9—liver cancer	7.09e-07	9.71e-06	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—VEGFA—liver cancer	7.08e-07	9.71e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—CTNNB1—liver cancer	7.08e-07	9.7e-06	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—VEGFA—liver cancer	7.07e-07	9.68e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—CDKN1A—liver cancer	7.06e-07	9.68e-06	CbGpPWpGaD
Pazopanib—FGFR3—Signaling Pathways—AKT1—liver cancer	7.05e-07	9.66e-06	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—STAT3—liver cancer	7.01e-07	9.61e-06	CbGpPWpGaD
Pazopanib—FGFR1—Disease—IL6—liver cancer	7e-07	9.59e-06	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—STAT3—liver cancer	7e-07	9.59e-06	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—MYC—liver cancer	6.99e-07	9.58e-06	CbGpPWpGaD
Pazopanib—FGFR1—Immune System—AKT1—liver cancer	6.99e-07	9.58e-06	CbGpPWpGaD
Pazopanib—PDGFRA—Disease—IL6—liver cancer	6.98e-07	9.56e-06	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—TGFB1—liver cancer	6.98e-07	9.56e-06	CbGpPWpGaD
Pazopanib—PDGFRA—Immune System—AKT1—liver cancer	6.97e-07	9.55e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—GOT1—liver cancer	6.97e-07	9.55e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—GGT1—liver cancer	6.97e-07	9.55e-06	CbGpPWpGaD
Pazopanib—LYN—Immune System—HRAS—liver cancer	6.97e-07	9.54e-06	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—HRAS—liver cancer	6.96e-07	9.53e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—MMP9—liver cancer	6.94e-07	9.51e-06	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—TP53—liver cancer	6.94e-07	9.51e-06	CbGpPWpGaD
Pazopanib—FGFR2—Disease—AKT1—liver cancer	6.92e-07	9.49e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—CDKN1A—liver cancer	6.92e-07	9.48e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—MAPK8—liver cancer	6.89e-07	9.45e-06	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—MYC—liver cancer	6.87e-07	9.41e-06	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—TGFB1—liver cancer	6.85e-07	9.39e-06	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—IL6—liver cancer	6.83e-07	9.36e-06	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—CYP1A1—liver cancer	6.83e-07	9.36e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—IL6—liver cancer	6.81e-07	9.33e-06	CbGpPWpGaD
Pazopanib—KIT—Disease—AKT1—liver cancer	6.8e-07	9.32e-06	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—GSTM1—liver cancer	6.79e-07	9.3e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—MAPK8—liver cancer	6.75e-07	9.25e-06	CbGpPWpGaD
Pazopanib—LCK—Immune System—KRAS—liver cancer	6.72e-07	9.2e-06	CbGpPWpGaD
Pazopanib—LCK—Disease—MYC—liver cancer	6.71e-07	9.2e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—RAF1—liver cancer	6.7e-07	9.19e-06	CbGpPWpGaD
Pazopanib—LCK—Disease—TGFB1—liver cancer	6.69e-07	9.17e-06	CbGpPWpGaD
Pazopanib—LYN—Immune System—IL6—liver cancer	6.67e-07	9.13e-06	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—IL6—liver cancer	6.66e-07	9.12e-06	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—HRAS—liver cancer	6.64e-07	9.09e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—HRAS—liver cancer	6.57e-07	9e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—MTOR—liver cancer	6.54e-07	8.97e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—PIK3CB—liver cancer	6.54e-07	8.97e-06	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—MYC—liver cancer	6.52e-07	8.93e-06	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—TGFB1—liver cancer	6.5e-07	8.91e-06	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—MYC—liver cancer	6.5e-07	8.91e-06	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—TGFB1—liver cancer	6.48e-07	8.89e-06	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—KRAS—liver cancer	6.46e-07	8.85e-06	CbGpPWpGaD
Pazopanib—FGFR1—Disease—AKT1—liver cancer	6.45e-07	8.84e-06	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	6.44e-07	8.83e-06	CbGpPWpGaD
Pazopanib—PDGFRA—Disease—AKT1—liver cancer	6.44e-07	8.82e-06	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—CYP1A1—liver cancer	6.44e-07	8.82e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—PSMD10—liver cancer	6.4e-07	8.78e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—PSMA4—liver cancer	6.4e-07	8.78e-06	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—MTHFR—liver cancer	6.37e-07	8.73e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—VEGFA—liver cancer	6.36e-07	8.72e-06	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—IL6—liver cancer	6.35e-07	8.7e-06	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—KRAS—liver cancer	6.35e-07	8.69e-06	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—AKT1—liver cancer	6.3e-07	8.64e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—STAT3—liver cancer	6.3e-07	8.64e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—IL6—liver cancer	6.29e-07	8.61e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—AKT1—liver cancer	6.28e-07	8.61e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—GSTP1—liver cancer	6.26e-07	8.58e-06	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—PPARA—liver cancer	6.25e-07	8.56e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—VEGFA—liver cancer	6.23e-07	8.54e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—GOT2—liver cancer	6.23e-07	8.54e-06	CbGpPWpGaD
Pazopanib—LCK—Disease—KRAS—liver cancer	6.2e-07	8.5e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—HMOX1—liver cancer	6.17e-07	8.46e-06	CbGpPWpGaD
Pazopanib—LCK—Immune System—PIK3CA—liver cancer	6.17e-07	8.46e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—STAT3—liver cancer	6.17e-07	8.46e-06	CbGpPWpGaD
Pazopanib—LYN—Immune System—AKT1—liver cancer	6.15e-07	8.43e-06	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—AKT1—liver cancer	6.14e-07	8.42e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—CDKN1B—liver cancer	6.14e-07	8.42e-06	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—PIK3CG—liver cancer	6.14e-07	8.41e-06	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—KRAS—liver cancer	6.02e-07	8.25e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—CASP3—liver cancer	6.02e-07	8.25e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—IL2—liver cancer	6.01e-07	8.24e-06	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—KRAS—liver cancer	6.01e-07	8.23e-06	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—MTHFR—liver cancer	6e-07	8.22e-06	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—PIK3CA—liver cancer	5.94e-07	8.13e-06	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—PPARG—liver cancer	5.93e-07	8.12e-06	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—PPARA—liver cancer	5.89e-07	8.07e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—CCND1—liver cancer	5.86e-07	8.03e-06	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—AKT1—liver cancer	5.86e-07	8.03e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—CYP2E1—liver cancer	5.86e-07	8.03e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—MYC—liver cancer	5.86e-07	8.02e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—JUN—liver cancer	5.85e-07	8.01e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—TGFB1—liver cancer	5.84e-07	8.01e-06	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—PIK3CA—liver cancer	5.83e-07	7.99e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—CTNNB1—liver cancer	5.8e-07	7.95e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—AKT1—liver cancer	5.8e-07	7.95e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—GSTM1—liver cancer	5.75e-07	7.88e-06	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—TP53—liver cancer	5.74e-07	7.87e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—MYC—liver cancer	5.73e-07	7.86e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—TGFB1—liver cancer	5.72e-07	7.84e-06	CbGpPWpGaD
Pazopanib—LCK—Immune System—HRAS—liver cancer	5.71e-07	7.82e-06	CbGpPWpGaD
Pazopanib—LCK—Disease—PIK3CA—liver cancer	5.7e-07	7.81e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—MMP9—liver cancer	5.69e-07	7.79e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—CDKN1A—liver cancer	5.67e-07	7.77e-06	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—TP53—liver cancer	5.64e-07	7.73e-06	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—PIK3CA—liver cancer	5.53e-07	7.58e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—MAPK8—liver cancer	5.53e-07	7.58e-06	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—PIK3CA—liver cancer	5.52e-07	7.56e-06	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—HRAS—liver cancer	5.49e-07	7.53e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—CYCS—liver cancer	5.48e-07	7.51e-06	CbGpPWpGaD
Pazopanib—LCK—Immune System—IL6—liver cancer	5.46e-07	7.49e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—CYP1A1—liver cancer	5.45e-07	7.47e-06	CbGpPWpGaD
Pazopanib—UGT1A1—Metabolism—PIK3CA—liver cancer	5.45e-07	7.46e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—KRAS—liver cancer	5.41e-07	7.42e-06	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—PIK3CD—liver cancer	5.4e-07	7.4e-06	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—HRAS—liver cancer	5.39e-07	7.39e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—GGT1—liver cancer	5.38e-07	7.37e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—GOT1—liver cancer	5.38e-07	7.37e-06	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—TP53—liver cancer	5.35e-07	7.33e-06	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—PIK3CG—liver cancer	5.35e-07	7.33e-06	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—TP53—liver cancer	5.34e-07	7.32e-06	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—ALB—liver cancer	5.33e-07	7.3e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—KRAS—liver cancer	5.3e-07	7.26e-06	CbGpPWpGaD
Pazopanib—LCK—Disease—HRAS—liver cancer	5.27e-07	7.22e-06	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—IL6—liver cancer	5.26e-07	7.2e-06	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—PPARG—liver cancer	5.16e-07	7.08e-06	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—IL6—liver cancer	5.16e-07	7.07e-06	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—HRAS—liver cancer	5.12e-07	7.01e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—VEGFA—liver cancer	5.11e-07	7e-06	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—HRAS—liver cancer	5.11e-07	7e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—MTHFR—liver cancer	5.08e-07	6.97e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—STAT3—liver cancer	5.06e-07	6.93e-06	CbGpPWpGaD
Pazopanib—LCK—Disease—IL6—liver cancer	5.04e-07	6.91e-06	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—PIK3CG—liver cancer	5.04e-07	6.91e-06	CbGpPWpGaD
Pazopanib—LCK—Immune System—AKT1—liver cancer	5.04e-07	6.91e-06	CbGpPWpGaD
Pazopanib—SLCO1B1—Metabolism—PIK3CA—liver cancer	4.99e-07	6.84e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—PPARA—liver cancer	4.99e-07	6.83e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—PIK3CA—liver cancer	4.97e-07	6.81e-06	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—IL6—liver cancer	4.9e-07	6.71e-06	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—IL6—liver cancer	4.89e-07	6.7e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—PIK3CA—liver cancer	4.87e-07	6.67e-06	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—PPARG—liver cancer	4.87e-07	6.67e-06	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—AKT1—liver cancer	4.85e-07	6.64e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—GSTP1—liver cancer	4.83e-07	6.62e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—TP53—liver cancer	4.81e-07	6.59e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—HMOX1—liver cancer	4.76e-07	6.53e-06	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—AKT1—liver cancer	4.76e-07	6.53e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—TP53—liver cancer	4.71e-07	6.45e-06	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—PIK3CB—liver cancer	4.71e-07	6.45e-06	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—PIK3CD—liver cancer	4.7e-07	6.44e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—MYC—liver cancer	4.7e-07	6.44e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—TGFB1—liver cancer	4.69e-07	6.42e-06	CbGpPWpGaD
Pazopanib—LCK—Disease—AKT1—liver cancer	4.65e-07	6.38e-06	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—ALB—liver cancer	4.64e-07	6.36e-06	CbGpPWpGaD
Pazopanib—ABCG2—Metabolism—PIK3CA—liver cancer	4.62e-07	6.33e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—HRAS—liver cancer	4.6e-07	6.3e-06	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—AKT1—liver cancer	4.52e-07	6.19e-06	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—AKT1—liver cancer	4.51e-07	6.18e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—HRAS—liver cancer	4.5e-07	6.17e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	4.48e-07	6.14e-06	CbGpPWpGaD
Pazopanib—UGT1A1—Metabolism—AKT1—liver cancer	4.45e-07	6.1e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—GSTM1—liver cancer	4.44e-07	6.08e-06	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—PIK3CD—liver cancer	4.43e-07	6.07e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—IL6—liver cancer	4.4e-07	6.03e-06	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—ALB—liver cancer	4.38e-07	6e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—KRAS—liver cancer	4.34e-07	5.95e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—IL6—liver cancer	4.31e-07	5.91e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—PIK3CG—liver cancer	4.27e-07	5.85e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—CYP1A1—liver cancer	4.21e-07	5.77e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—PPARG—liver cancer	4.12e-07	5.65e-06	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—PIK3CB—liver cancer	4.1e-07	5.62e-06	CbGpPWpGaD
Pazopanib—SLCO1B1—Metabolism—AKT1—liver cancer	4.08e-07	5.59e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—AKT1—liver cancer	4.06e-07	5.57e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—PIK3CA—liver cancer	3.99e-07	5.47e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—AKT1—liver cancer	3.98e-07	5.45e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—MTHFR—liver cancer	3.92e-07	5.38e-06	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—PIK3CB—liver cancer	3.86e-07	5.29e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—TP53—liver cancer	3.86e-07	5.29e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—PPARA—liver cancer	3.85e-07	5.27e-06	CbGpPWpGaD
Pazopanib—ABCG2—Metabolism—AKT1—liver cancer	3.78e-07	5.17e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—PIK3CD—liver cancer	3.75e-07	5.14e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—ALB—liver cancer	3.71e-07	5.08e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—HRAS—liver cancer	3.69e-07	5.06e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—IL6—liver cancer	3.53e-07	4.84e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—PIK3CG—liver cancer	3.3e-07	4.52e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—PIK3CB—liver cancer	3.27e-07	4.48e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—AKT1—liver cancer	3.26e-07	4.47e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—PPARG—liver cancer	3.18e-07	4.36e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—PIK3CD—liver cancer	2.9e-07	3.97e-06	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—PIK3CA—liver cancer	2.87e-07	3.93e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—ALB—liver cancer	2.86e-07	3.92e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—PIK3CB—liver cancer	2.53e-07	3.46e-06	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—PIK3CA—liver cancer	2.5e-07	3.42e-06	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—PIK3CA—liver cancer	2.35e-07	3.23e-06	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—AKT1—liver cancer	2.34e-07	3.21e-06	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—AKT1—liver cancer	2.04e-07	2.8e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—PIK3CA—liver cancer	1.99e-07	2.73e-06	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—AKT1—liver cancer	1.92e-07	2.64e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—AKT1—liver cancer	1.63e-07	2.23e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—PIK3CA—liver cancer	1.54e-07	2.11e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—AKT1—liver cancer	1.26e-07	1.72e-06	CbGpPWpGaD
